CTNNB1/APC (β-Catenin/Adenomatous Polyposis Coli; WNT Pathway) affects WNT/β-catenin signaling via CTNNB1 activation or APC loss, promoting LUAD (pan-NSCLC) progression and immune evasion; recent reviews in NSCLC outline therapeutic avenues to block this axis [114]. This evidence concerns the gene CTNNB1 and non-small cell lung carcinoma.